Table 3: The Values of Lymphocytes at Baseline and After 6 Months of Anti-TNFa Treatment
Cells |
ADA Group
Week 0 |
ETN Group
Week 0 |
IFN Group
Week 0 |
Normal Value in
Donors Age Matched |
P
Value |
ADA Group
Week 24 |
ETN Group
Week 24 |
IFN Group
Week 24 |
P
Value |
CD3+ |
1734±657 |
1725±688 |
1724±637 |
1100-1700 |
NS |
1838±632 |
1653±736 |
1645±624 |
NS |
CD3+/CD4+ |
1734±657 |
1134±317 |
1158±366 |
650-1400 |
NS |
1250±496 |
1065±562 |
1067±446 |
NS |
CD3+/CD8+ |
470±210 |
445±218 |
480±205 |
320-900 |
NS |
520±230 |
489±223 |
534±321 |
NS |
CD19+ |
268±89 |
245±92 |
259±91 |
200-400 |
NS |
273±143 |
261±202 |
255±174 |
NS |
CD20+ |
198±156 |
191±146 |
188±126 |
150-400 |
NS |
193±179 |
164±85 |
99±17 |
NS |
CD19+/CD38+ |
234±143 |
223±133 |
214±163 |
150-400 |
NS |
240±155 |
109±74 |
79±15 |
NS |
CD16+/56+ |
211±72 |
217±68 |
213±67 |
200-400 |
NS |
219±87 |
211±54 |
210±45 |
NS |
CD14+HLADR+% |
57±12 |
55±14 |
59±12 |
50-90 |
NS |
54.6±10.4 |
48.4±15.7 |
40.7±16.5 |
<0.039 |
CD14+HLADR+ |
345±213. |
335±223 |
349±209 |
300-400 |
NS |
326±214 |
311±230. |
246±78 |
<0.05 |